Fate Therapeutics Inc logo

Fate Therapeutics Inc

€ 6.26 (-1.71%) Feb 8
P/E:
At Loss
P/B:
1.28
Market Cap:
€ 619.52M ($ 664.88M)
Enterprise V:
€ 252.07M ($ 270.53M)
Volume:
131.00
Avg Vol (2M):
1.23K
Also Trade In:
Volume:
131.00
Market Cap €:
619.52M
Market Cap $:
664.88M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.23K
Enterprise Value €:
252.07M
Enterprise Value $:
270.53M
PB Ratio:
1.28

Business Description

Description
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Name Current Vs Industry Vs History
Cash-To-Debt 4.55
Equity-to-Asset 0.69
Debt-to-Equity 0.21
Debt-to-EBITDA -0.37
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.65
Distress
Grey
Safe
Beneish M-Score -3.06
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 68.31
9-Day RSI 54.03
14-Day RSI 42.55
6-1 Month Momentum % -88.56
12-1 Month Momentum % -88.33

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.15
Quick Ratio 5.15
Cash Ratio 4.86
Days Sales Outstanding 56.26

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -14

Financials (Next Earnings Date:2023-02-28 Est.)

FRA:F6T's 30-Y Financials

How Fate Therapeutics Inc (FRA:F6T) Makes Its Money

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Executives

Details

Valuation chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 64.504
EPS (TTM) (€) -2.87
Beta 0.95
Volatility % 79.77
14-Day RSI 42.55
14-Day ATR (€) 0.396927
20-Day SMA (€) 5.440675
12-1 Month Momentum % -88.33
52-Week Range (€) 3.8555 - 38.42
Shares Outstanding (Mil) 97.17

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Fate Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Fate Therapeutics Inc Stock Events

Event Date Price(€)
No Event Data

Press Release

Subject Date
No Press Release